Clinical Trial Update: Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of gefitinib (Iressa) for brain metastases from non-small cell lung cancer was terminated. The study was sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Brain Neoplasms, Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED